S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
BREAKING: Tiny biotech successfully treats blindness (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
BREAKING: Tiny biotech successfully treats blindness (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The UAE holds an annual oil and gas conference just ahead of hosting UN COP28 climate talks in Dubai
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
BREAKING: Tiny biotech successfully treats blindness (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
BREAKING: Tiny biotech successfully treats blindness (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The UAE holds an annual oil and gas conference just ahead of hosting UN COP28 climate talks in Dubai
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
BREAKING: Tiny biotech successfully treats blindness (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
BREAKING: Tiny biotech successfully treats blindness (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The UAE holds an annual oil and gas conference just ahead of hosting UN COP28 climate talks in Dubai
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
BREAKING: Tiny biotech successfully treats blindness (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
BREAKING: Tiny biotech successfully treats blindness (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The UAE holds an annual oil and gas conference just ahead of hosting UN COP28 climate talks in Dubai

Immunovant (IMVT) Stock Forecast, Price & News

$38.39
-1.40 (-3.52%)
(As of 09/29/2023 08:53 PM ET)
Compare
Today's Range
$37.97
$40.74
50-Day Range
$19.59
$39.96
52-Week Range
$5.09
$44.19
Volume
2.57 million shs
Average Volume
1.35 million shs
Market Capitalization
$5.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.83

Immunovant MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
9.3% Downside
$34.83 Price Target
Short Interest
Bearish
9.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of Immunovant in the last 14 days
Based on 45 Articles This Week
Insider Trading
Selling Shares
$6.46 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.91) to ($1.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

Medical Sector

895th out of 970 stocks

Biological Products, Except Diagnostic Industry

147th out of 156 stocks


IMVT stock logo

About Immunovant (NASDAQ:IMVT) Stock

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

IMVT Price History

IMVT Stock News Headlines

Immunovant (NASDAQ:IMVT) Stock Price Down 4.4%
The World's First "$20 Trillion Drug
?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>
Immunovant (NASDAQ:IMVT) PT Raised to $48.00
Citigroup Boosts Immunovant (NASDAQ:IMVT) Price Target to $50.00
U.S. "Shadow Banks" About to Blow up again?
Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.
Immunovant (NASDAQ:IMVT) Given New $48.00 Price Target at Guggenheim
Immunovant (NASDAQ:IMVT) Shares Gap Up on Analyst Upgrade
Raymond James Upgrades Immunovant (IMVT)
Truist Financial Reiterates "Buy" Rating for Immunovant (NASDAQ:IMVT)
Raymond James Upgrades Immunovant (NASDAQ:IMVT) to "Outperform"
Why Shares of Immunovant Are Soaring on Tuesday
See More Headlines
Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

IMVT Company Calendar

Last Earnings
8/10/2023
Today
10/02/2023
Next Earnings (Estimated)
11/03/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMVT
Fax
N/A
Employees
164
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$34.83
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
-9.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-210,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.78 per share

Miscellaneous

Free Float
124,400,000
Market Cap
$5.02 billion
Optionable
Not Optionable
Beta
0.91
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Frank M. Torti M.B.A. (Age 44)
    M.D., MBA, Exec. Chairperson of the Board
    Comp: $92.5k
  • Dr. Peter  Salzmann M.B.A.Dr. Peter Salzmann M.B.A. (Age 55)
    M.D., CEO & Director
    Comp: $1.02M
  • Ms. Eva Renee Barnett M.B.A. (Age 43)
    Chief Financial Officer
    Comp: $871.07k
  • Dr. William L. Macias M.D. (Age 65)
    Ph.D., Chief Medical Officer
    Comp: $719.88k
  • Dr. Jay S. Stout Ph.D. (Age 60)
    Chief Technology Officer
  • Dr. Chau Cheng M.B.A.
    Ph.D., VP of Investor Relations
  • Mr. Mark S. Levine (Age 50)
    Chief Legal Officer & Corp. Sec.
  • Ms. Lauren Schrier M.B.A.
    VP of Marketing
  • Ms. Christine Blodgett
    VP of HR
  • Dr. Julia G. Butchko Ph.D. (Age 52)
    Chief Devel. Officer













IMVT Stock - Frequently Asked Questions

Should I buy or sell Immunovant stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMVT shares.
View IMVT analyst ratings
or view top-rated stocks.

What is Immunovant's stock price forecast for 2023?

12 Wall Street analysts have issued 12-month target prices for Immunovant's shares. Their IMVT share price forecasts range from $21.00 to $50.00. On average, they expect the company's stock price to reach $34.83 in the next year. This suggests that the stock has a possible downside of 9.3%.
View analysts price targets for IMVT
or view top-rated stocks among Wall Street analysts.

How have IMVT shares performed in 2023?

Immunovant's stock was trading at $17.75 at the start of the year. Since then, IMVT shares have increased by 116.3% and is now trading at $38.39.
View the best growth stocks for 2023 here
.

When is Immunovant's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023.
View our IMVT earnings forecast
.

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) issued its earnings results on Thursday, August, 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.03.

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).

What is Immunovant's stock symbol?

Immunovant trades on the NASDAQ under the ticker symbol "IMVT."

How do I buy shares of Immunovant?

Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunovant's stock price today?

One share of IMVT stock can currently be purchased for approximately $38.39.

How much money does Immunovant make?

Immunovant (NASDAQ:IMVT) has a market capitalization of $5.02 billion. The company earns $-210,960,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does Immunovant have?

The company employs 164 workers across the globe.

How can I contact Immunovant?

Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The official website for the company is www.immunovant.com. The company can be reached via phone at 917-580-3099 or via email at info@immunovant.com.

This page (NASDAQ:IMVT) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -